{"id":"https://openalex.org/W4362546277","doi":"https://doi.org/10.1158/2326-6066.c.6548914","title":"Data from Soluble PD-L1 as a Biomarker in Malignant Melanoma Treated with Checkpoint Blockade","display_name":"Data from Soluble PD-L1 as a Biomarker in Malignant Melanoma Treated with Checkpoint Blockade","publication_year":2023,"publication_date":"2023-04-03","ids":{"openalex":"https://openalex.org/W4362546277","doi":"https://doi.org/10.1158/2326-6066.c.6548914"},"language":"en","primary_location":{"id":"doi:10.1158/2326-6066.c.6548914","doi":"https://doi.org/10.1158/2326-6066.c.6548914","is_oa":true,"landing_page_url":"https://doi.org/10.1158/2326-6066.c.6548914","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"volume":null,"type":"other","indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://doi.org/10.1158/2326-6066.c.6548914","any_repository_has_fulltext":null},"authorships":[{"author_position":"first","author":{"id":null,"display_name":"Jun Zhou","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jun Zhou","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5038736877","display_name":"Kathleen Margaret Mahoney","orcid":"https://orcid.org/0000-0002-3869-6803","observed_orcids":["https://orcid.org/0000-0002-3869-6803"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Kathleen M. Mahoney","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5071788399","display_name":"Anita Giobbie\u2010Hurder","orcid":"https://orcid.org/0000-0003-2496-7737","observed_orcids":["https://orcid.org/0000-0003-2496-7737"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Anita Giobbie-Hurder","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5101198502","display_name":"Fengmin Zhao","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Fengmin Zhao","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":null,"display_name":"Sandra Lee","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Sandra Lee","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100569863","display_name":"Xiaoyun Liao","orcid":"https://orcid.org/0009-0000-8904-0102","observed_orcids":["https://orcid.org/0009-0000-8904-0102"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Xiaoyun Liao","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5058975989","display_name":"Scott J. Rodig","orcid":"https://orcid.org/0000-0003-1761-9769","observed_orcids":["https://orcid.org/0000-0003-1761-9769"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Scott Rodig","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100338383","display_name":"Jingjing Li","orcid":"https://orcid.org/0000-0002-4410-2629","observed_orcids":["https://orcid.org/0000-0002-4410-2629"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jingjing Li","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103093153","display_name":"Xinqi Wu","orcid":"https://orcid.org/0000-0003-4979-4596","observed_orcids":["https://orcid.org/0000-0003-4979-4596"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Xinqi Wu","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5026029856","display_name":"Lisa Helene Butterfield","orcid":"https://orcid.org/0000-0002-3439-9844","observed_orcids":["https://orcid.org/0000-0002-3439-9844"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Lisa H. Butterfield","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5032855671","display_name":"Matthias Piesche","orcid":"https://orcid.org/0000-0002-9050-1946","observed_orcids":["https://orcid.org/0000-0002-9050-1946"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Matthias Piesche","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5070590609","display_name":"Michael P. Manos","orcid":"https://orcid.org/0000-0003-0841-207X","observed_orcids":["https://orcid.org/0000-0003-0841-207X","https://orcid.org/0000-0001-9766-0977"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Michael P. Manos","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5088118544","display_name":"Lauren M. Eastman","orcid":"https://orcid.org/0009-0009-5757-843X","observed_orcids":["https://orcid.org/0009-0009-5757-843X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Lauren M. Eastman","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5028608171","display_name":"Glenn Dranoff","orcid":"https://orcid.org/0000-0002-2341-7517","observed_orcids":["https://orcid.org/0000-0002-2341-7517"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Glenn Dranoff","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5075310347","display_name":"Gordon James Freeman","orcid":"https://orcid.org/0000-0002-7210-5616","observed_orcids":["https://orcid.org/0000-0002-7210-5616"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Gordon J. Freeman","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5084967339","display_name":"Frank Stephen Hodi","orcid":"https://orcid.org/0000-0001-6825-091X","observed_orcids":["https://orcid.org/0000-0001-6825-091X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"F. Stephen Hodi","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10392","display_name":"Cutaneous Melanoma Detection and Management","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10031","display_name":"T-cell and B-cell Immunology","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/soluble-pd-l1","display_name":"soluble PD-L1","score":1.0},{"id":"https://openalex.org/keywords/melanoma","display_name":"melanoma","score":0.8420000076293945},{"id":"https://openalex.org/keywords/immune-checkpoint-blockade","display_name":"immune checkpoint blockade","score":0.9129999876022339},{"id":"https://openalex.org/keywords/anti-pd-1-therapy","display_name":"anti-PD-1 therapy","score":0.828000009059906},{"id":"https://openalex.org/keywords/ctla-4-blockade","display_name":"CTLA-4 blockade","score":1.0},{"id":"https://openalex.org/keywords/prognostic-factors","display_name":"prognostic factors","score":0.9330000281333923},{"id":"https://openalex.org/keywords/circulating-biomarkers","display_name":"circulating biomarkers","score":0.5189999938011169},{"id":"https://openalex.org/keywords/alternative-splicing","display_name":"alternative splicing","score":0.8420000076293945},{"id":"https://openalex.org/keywords/cytokine-induction","display_name":"cytokine induction","score":0.699999988079071},{"id":"https://openalex.org/keywords/treatment-response-prediction","display_name":"treatment response prediction","score":0.7129999995231628},{"id":"https://openalex.org/keywords/stage-iv-melanoma","display_name":"stage IV melanoma","score":0.781000018119812}],"concepts":[{"id":"https://openalex.org/C2778468042","wikidata":"https://www.wikidata.org/wiki/Q273976","display_name":"Blockade","level":3,"score":0.8805345296859741},{"id":"https://openalex.org/C2780851360","wikidata":"https://www.wikidata.org/wiki/Q21686041","display_name":"Immune checkpoint","level":4,"score":0.7401402592658997},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6542730331420898},{"id":"https://openalex.org/C2777658100","wikidata":"https://www.wikidata.org/wiki/Q180614","display_name":"Melanoma","level":2,"score":0.6448626518249512},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.5383762717247009},{"id":"https://openalex.org/C2781053074","wikidata":"https://www.wikidata.org/wiki/Q21100639","display_name":"PD-L1","level":4,"score":0.5377089977264404},{"id":"https://openalex.org/C2781197716","wikidata":"https://www.wikidata.org/wiki/Q864574","display_name":"Biomarker","level":2,"score":0.479783833026886},{"id":"https://openalex.org/C8891405","wikidata":"https://www.wikidata.org/wiki/Q1059","display_name":"Immune system","level":2,"score":0.43864428997039795},{"id":"https://openalex.org/C2780030458","wikidata":"https://www.wikidata.org/wiki/Q7041828","display_name":"Nivolumab","level":4,"score":0.4370262622833252},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.42016133666038513},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.4162941575050354},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.36480915546417236},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.35605061054229736},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.3280791938304901},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.28145459294319153},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.16576510667800903},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.0}],"mesh":[],"locations_count":2,"locations":[{"id":"doi:10.1158/2326-6066.c.6548914","doi":"https://doi.org/10.1158/2326-6066.c.6548914","is_oa":true,"landing_page_url":"https://doi.org/10.1158/2326-6066.c.6548914","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},{"id":"doi:10.1158/2326-6066.c.6548914.v1","doi":"https://doi.org/10.1158/2326-6066.c.6548914.v1","is_oa":true,"landing_page_url":"http://dx.doi.org/10.1158/2326-6066.c.6548914.v1","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"}],"best_oa_location":{"id":"doi:10.1158/2326-6066.c.6548914","doi":"https://doi.org/10.1158/2326-6066.c.6548914","is_oa":true,"landing_page_url":"https://doi.org/10.1158/2326-6066.c.6548914","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"sustainable_development_goals":[{"score":0.9940000176429749,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2615907969","https://openalex.org/W3204182287","https://openalex.org/W4362464765","https://openalex.org/W4392372011","https://openalex.org/W2797075366","https://openalex.org/W2904253493","https://openalex.org/W4387186940","https://openalex.org/W2740300715","https://openalex.org/W3100325506","https://openalex.org/W3088147467"],"abstract_inverted_index":{"Abstract":[0],"Blockade":[1],"of":[2,28,32,55,74,81,86,107,124,131,162,178,184,212],"the":[3,50],"pathway":[4],"including":[5],"programmed":[6,13],"death-ligand":[7],"1":[8,17],"(PD-L1)":[9],"and":[10,46,53,79,99],"its":[11],"receptor":[12],"cell":[14,44,95,97,100],"death":[15,101],"protein":[16],"(PD-1)":[18],"has":[19],"produced":[20],"clinical":[21],"benefits":[22],"in":[23,42,58,76,102,111,134,144],"patients":[24,135,169,213],"with":[25,39,60,118,128,156,188],"a":[26,180,203],"variety":[27],"cancers.":[29],"Elevated":[30],"levels":[31,106,123],"soluble":[33],"PD-L1":[34,75],"(sPD-L1)":[35],"have":[36],"been":[37],"associated":[38,127,187],"worse":[40],"prognosis":[41],"renal":[43],"carcinoma":[45],"multiple":[47],"myeloma.":[48],"However,":[49],"regulatory":[51],"roles":[52],"function":[54],"sPD-L1":[56,87,108,125,146,174,185,201],"particularly":[57],"connection":[59],"immune":[61],"checkpoint":[62,215],"blockade":[63,168,194],"treatment":[64,149,163],"are":[65,83],"not":[66,151,196],"fully":[67],"understood.":[68],"We":[69],"identified":[70],"four":[71],"splice":[72],"variants":[73],"melanoma":[77,103,114],"cells,":[78],"all":[80],"them":[82],"secreted.":[84],"Secretion":[85],"resulted":[88],"from":[89,154],"alternate":[90],"splicing":[91],"activities,":[92],"cytokine":[93],"induction,":[94],"stress,":[96],"injury,":[98],"cells.":[104],"Pretreatment":[105],"were":[109,126],"elevated":[110],"stage":[112],"IV":[113],"patient":[115],"sera":[116],"compared":[117],"healthy":[119],"donors.":[120],"High":[121],"pretreatment":[122],"increased":[129,172,189],"likelihood":[130,177],"progressive":[132,157],"disease":[133],"treated":[136],"by":[137,164],"CTLA-4":[138,165,193],"or":[139,166],"PD-1":[140,167,198],"blockade.":[141,199],"Although":[142],"changes":[143],"circulating":[145,173,190],"early":[147],"after":[148,159,192],"could":[150],"distinguish":[152],"responders":[153],"those":[155],"disease,":[158],"five":[160],"months":[161],"who":[170],"had":[171,175],"greater":[176],"developing":[179],"partial":[181],"response.":[182],"Induction":[183],"was":[186],"cytokines":[191],"but":[195],"following":[197],"Circulating":[200],"is":[202],"prognostic":[204],"biomarker":[205],"that":[206],"may":[207],"predict":[208],"outcomes":[209],"for":[210],"subgroups":[211],"receiving":[214],"inhibitors.":[216],"Cancer":[217],"Immunol":[218],"Res;":[219],"5(6);":[220],"480\u201392.":[221],"\u00a92017":[222],"AACR.":[223]},"counts_by_year":[],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2023-04-06T00:00:00"}